CR20200453A - Uso de inhibidores de fubp1 para el tratamiento de infección de virús de hepatitis b - Google Patents
Uso de inhibidores de fubp1 para el tratamiento de infección de virús de hepatitis bInfo
- Publication number
- CR20200453A CR20200453A CR20200453A CR20200453A CR20200453A CR 20200453 A CR20200453 A CR 20200453A CR 20200453 A CR20200453 A CR 20200453A CR 20200453 A CR20200453 A CR 20200453A CR 20200453 A CR20200453 A CR 20200453A
- Authority
- CR
- Costa Rica
- Prior art keywords
- fubp1
- virus infection
- treating hepatitis
- inhibitors
- relates
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 208000002672 hepatitis B Diseases 0.000 title 1
- 102100036118 Far upstream element-binding protein 1 Human genes 0.000 abstract 4
- 101000930770 Homo sapiens Far upstream element-binding protein 1 Proteins 0.000 abstract 4
- 208000015181 infectious disease Diseases 0.000 abstract 3
- 108091036055 CccDNA Proteins 0.000 abstract 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 108091027967 Small hairpin RNA Proteins 0.000 abstract 1
- 108020004459 Small interfering RNA Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 1
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 230000000368 destabilizing effect Effects 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000002924 silencing RNA Substances 0.000 abstract 1
- 239000004055 small Interfering RNA Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
<p>La presente invención se relaciona con un inhibidor de FUBP1 para uso en el tratamiento de una infección de HBV, en particular una infección de HBV crónica. La invención en particular se relaciona con el uso de inhibidores de FUBP1 para desestabilizar ADNccc, tal como ADNccc de HBV. La invención también se relaciona con moléculas de ácido nucleico, tales como oligonucleótidos incluyendo ARNip, ARNhc y oligonucleótidos anti sentido, que son complementarios a FUBP1 y capaces de reducir el ARNm de FUBP1. También comprendida en la presente invención es una composición</p> <p>farmacéutica y su uso en el tratamiento y/o la prevención de una</p> <p>infección de HBV.</p>
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18165897 | 2018-04-05 | ||
PCT/EP2019/058664 WO2019193165A1 (en) | 2018-04-05 | 2019-04-05 | Use of fubp1 inhibitors for treating hepatitis b virus infection |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20200453A true CR20200453A (es) | 2021-03-02 |
Family
ID=61911421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20200453A CR20200453A (es) | 2018-04-05 | 2019-04-05 | Uso de inhibidores de fubp1 para el tratamiento de infección de virús de hepatitis b |
Country Status (18)
Country | Link |
---|---|
US (2) | US11732262B2 (es) |
EP (1) | EP3775208A1 (es) |
JP (1) | JP2021520387A (es) |
KR (1) | KR20200140853A (es) |
CN (1) | CN112055749A (es) |
AU (1) | AU2019247645A1 (es) |
BR (1) | BR112020020220A8 (es) |
CA (1) | CA3097544A1 (es) |
CL (1) | CL2020002563A1 (es) |
CR (1) | CR20200453A (es) |
IL (1) | IL277745A (es) |
MA (1) | MA52661A (es) |
MX (1) | MX2020010383A (es) |
PE (1) | PE20211912A1 (es) |
RU (1) | RU2020135289A (es) |
SG (1) | SG11202009680XA (es) |
TW (1) | TW202006138A (es) |
WO (1) | WO2019193165A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3775208A1 (en) | 2018-04-05 | 2021-02-17 | F. Hoffmann-La Roche AG | Use of fubp1 inhibitors for treating hepatitis b virus infection |
CN114829599A (zh) * | 2019-12-19 | 2022-07-29 | 豪夫迈·罗氏有限公司 | Scamp3抑制剂用于治疗乙型肝炎病毒感染的用途 |
AR122731A1 (es) | 2020-06-26 | 2022-10-05 | Hoffmann La Roche | Oligonucleótidos mejorados para modular la expresión de fubp1 |
JP2023538630A (ja) * | 2020-08-21 | 2023-09-08 | エフ. ホフマン-ラ ロシュ アーゲー | B型肝炎ウイルス感染症を処置するためのa1cf阻害剤の使用 |
WO2023111210A1 (en) | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Combination of oligonucleotides for modulating rtel1 and fubp1 |
CN115851725B (zh) * | 2022-10-28 | 2024-06-11 | 珠海市人民医院 | 一种抑制解螺旋酶Ⅴ基因表达的siRNA及其应用 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69233046T2 (de) | 1991-10-24 | 2004-03-04 | Isis Pharmaceuticals, Inc., Carlsfeld | Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen |
US5580760A (en) * | 1993-02-22 | 1996-12-03 | The United States Of America As Represented By The Department Of Health And Human Services | FUSE binding protein and cDNA therefor |
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
EP1557424A1 (en) | 1997-09-12 | 2005-07-27 | Exiqon A/S | Bi-cyclic nucleoside, nucleotide and oligonucleoide analogues |
BRPI0008131B8 (pt) | 1999-02-12 | 2021-05-25 | Daiichi Sankyo Co Ltd | composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno |
NZ514348A (en) | 1999-05-04 | 2004-05-28 | Exiqon As | L-ribo-LNA analogues |
US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
AU2003296897A1 (en) | 2002-08-20 | 2004-05-04 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
WO2004027061A1 (ja) * | 2002-09-17 | 2004-04-01 | Yamanouchi Pharmaceutical Co., Ltd. | 抗増殖性疾患治療薬のスクリーニング方法 |
DK1569661T3 (da) | 2002-11-18 | 2010-01-11 | Santaris Pharma As | Antisense design |
CN1836042A (zh) | 2003-06-12 | 2006-09-20 | 原子核物理公司 | 用于基因沉默的hbv和hcv保守序列 |
CN101052717A (zh) * | 2004-05-11 | 2007-10-10 | α基因株式会社 | 诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法 |
WO2006082053A1 (en) | 2005-02-02 | 2006-08-10 | Heidelberg Pharma Gmbh | 7-ethyl-10-hydroxy-camptothecin lipid ester derivatives |
WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
DK1984381T3 (da) | 2006-01-27 | 2010-11-01 | Isis Pharmaceuticals Inc | 6-modificerede bicycliske nukleinsyreanaloger |
WO2007143315A2 (en) | 2006-05-05 | 2007-12-13 | Isis Pharmaceutical, Inc. | Compounds and methods for modulating expression of pcsk9 |
CA2651453C (en) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
WO2008113832A2 (en) | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA |
US8278425B2 (en) | 2007-05-30 | 2012-10-02 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
DK2173760T4 (en) | 2007-06-08 | 2016-02-08 | Isis Pharmaceuticals Inc | Carbocyclic bicyclic nukleinsyreanaloge |
US8278283B2 (en) | 2007-07-05 | 2012-10-02 | Isis Pharmaceuticals, Inc. | 6-disubstituted or unsaturated bicyclic nucleic acid analogs |
US8546556B2 (en) | 2007-11-21 | 2013-10-01 | Isis Pharmaceuticals, Inc | Carbocyclic alpha-L-bicyclic nucleic acid analogs |
US8501805B2 (en) | 2008-09-24 | 2013-08-06 | Isis Pharmaceuticals, Inc. | Substituted alpha-L-bicyclic nucleosides |
CN102325534B (zh) | 2008-12-18 | 2016-02-17 | 戴瑟纳制药公司 | 延长的dicer酶底物和特异性抑制基因表达的方法 |
US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
EP2462153B1 (en) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
EP2512491B1 (en) | 2009-10-16 | 2017-10-11 | Glaxo Group Limited | Hbv antisense inhibitors |
US8846637B2 (en) | 2010-06-08 | 2014-09-30 | Isis Pharmaceuticals, Inc. | Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
AU2011292261B2 (en) | 2010-08-17 | 2015-05-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA) |
EP2633051B1 (en) | 2010-10-28 | 2016-09-14 | Benitec Biopharma Limited | Hbv treatment |
CN103502273A (zh) | 2011-04-20 | 2014-01-08 | 罗氏格黎卡特股份公司 | 用于pH依赖性通过血脑屏障的方法和构建体 |
EP3816288A3 (en) | 2011-04-21 | 2021-07-14 | Glaxo Group Limited | Modulation of hepatitis b virus (hbv) expression |
KR102554783B1 (ko) | 2011-06-30 | 2023-07-11 | 애로우헤드 파마슈티컬스 인코포레이티드 | B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법 |
WO2013022966A1 (en) | 2011-08-11 | 2013-02-14 | Isis Pharmaceuticals, Inc. | Linkage modified gapped oligomeric compounds and uses thereof |
WO2013033230A1 (en) | 2011-08-29 | 2013-03-07 | Isis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
US9221864B2 (en) | 2012-04-09 | 2015-12-29 | Isis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
WO2013159109A1 (en) | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
KR102112892B1 (ko) | 2012-11-15 | 2020-05-19 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | 올리고뉴클레오티드 콘쥬게이트 |
FR2998748B1 (fr) | 2012-11-23 | 2015-04-10 | Commissariat Energie Atomique | Dispositif et procede de retransmission de donnees dans un commutateur reseau |
JP6995478B2 (ja) | 2013-05-01 | 2022-01-14 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | Hbvおよびttr発現を調節するための組成物および方法 |
ES2770667T3 (es) | 2013-06-27 | 2020-07-02 | Roche Innovation Ct Copenhagen As | Oligómeros antisentido y conjugados que se dirigen a PCSK9 |
GB201408623D0 (en) | 2014-05-15 | 2014-07-02 | Santaris Pharma As | Oligomers and oligomer conjugates |
US10415037B2 (en) * | 2014-10-02 | 2019-09-17 | Arbutus Biopharma Corporation | Compositions and methods for silencing hepatitis B virus gene expression |
SG11201702877TA (en) | 2014-10-10 | 2017-05-30 | Hoffmann La Roche | Galnac phosphoramidites, nucleic acid conjugates thereof and their use |
JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
US10975442B2 (en) * | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
CN105777770B (zh) | 2014-12-26 | 2018-05-25 | 中国人民解放军第二军医大学 | 一种饱和长链脂肪酸修饰的7-乙基-10-羟基喜树碱化合物及其长循环脂质体 |
US20180023081A1 (en) | 2015-02-04 | 2018-01-25 | Bristol-Myers Squibb Company | Lna oligonucleotides with alternating flanks |
EP3325097B1 (en) | 2015-07-17 | 2021-09-01 | Arcturus Therapeutics, Inc. | Compositions and agents against hepatitis b virus and uses thereof |
US10130651B2 (en) | 2015-08-07 | 2018-11-20 | Arrowhead Pharmaceuticals, Inc. | RNAi Therapy for Hepatitis B Virus Infection |
WO2017178656A1 (en) | 2016-04-14 | 2017-10-19 | Roche Innovation Center Copenhagen A/S | TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE |
MA45496A (fr) | 2016-06-17 | 2019-04-24 | Hoffmann La Roche | Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b |
EP3775208A1 (en) | 2018-04-05 | 2021-02-17 | F. Hoffmann-La Roche AG | Use of fubp1 inhibitors for treating hepatitis b virus infection |
-
2019
- 2019-04-05 EP EP19714455.3A patent/EP3775208A1/en active Pending
- 2019-04-05 AU AU2019247645A patent/AU2019247645A1/en active Pending
- 2019-04-05 RU RU2020135289A patent/RU2020135289A/ru unknown
- 2019-04-05 CR CR20200453A patent/CR20200453A/es unknown
- 2019-04-05 WO PCT/EP2019/058664 patent/WO2019193165A1/en active Application Filing
- 2019-04-05 MA MA052661A patent/MA52661A/fr unknown
- 2019-04-05 JP JP2020554482A patent/JP2021520387A/ja active Pending
- 2019-04-05 MX MX2020010383A patent/MX2020010383A/es unknown
- 2019-04-05 BR BR112020020220A patent/BR112020020220A8/pt unknown
- 2019-04-05 CA CA3097544A patent/CA3097544A1/en active Pending
- 2019-04-05 CN CN201980023565.2A patent/CN112055749A/zh active Pending
- 2019-04-05 SG SG11202009680XA patent/SG11202009680XA/en unknown
- 2019-04-05 PE PE2020001470A patent/PE20211912A1/es unknown
- 2019-04-05 KR KR1020207031603A patent/KR20200140853A/ko active Search and Examination
- 2019-04-08 TW TW108112210A patent/TW202006138A/zh unknown
-
2020
- 2020-10-01 IL IL277745A patent/IL277745A/en unknown
- 2020-10-02 CL CL2020002563A patent/CL2020002563A1/es unknown
- 2020-10-05 US US17/063,610 patent/US11732262B2/en active Active
-
2023
- 2023-06-23 US US18/340,054 patent/US20240150758A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MA52661A (fr) | 2021-02-17 |
US20210024934A1 (en) | 2021-01-28 |
WO2019193165A1 (en) | 2019-10-10 |
US20240150758A1 (en) | 2024-05-09 |
CA3097544A1 (en) | 2019-10-10 |
IL277745A (en) | 2020-11-30 |
SG11202009680XA (en) | 2020-10-29 |
TW202006138A (zh) | 2020-02-01 |
BR112020020220A2 (pt) | 2021-01-19 |
PE20211912A1 (es) | 2021-09-28 |
RU2020135289A (ru) | 2022-05-05 |
US11732262B2 (en) | 2023-08-22 |
KR20200140853A (ko) | 2020-12-16 |
BR112020020220A8 (pt) | 2021-02-17 |
EP3775208A1 (en) | 2021-02-17 |
JP2021520387A (ja) | 2021-08-19 |
MX2020010383A (es) | 2020-12-10 |
AU2019247645A1 (en) | 2020-10-15 |
CL2020002563A1 (es) | 2021-05-07 |
CN112055749A (zh) | 2020-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20200453A (es) | Uso de inhibidores de fubp1 para el tratamiento de infección de virús de hepatitis b | |
MX367543B (es) | MOLÉCULAS DE ÁCIDO NUCLEICO PARA LA REDUCCIÓN DE ARNm DE PAPD5 O PAPD7 PARA TRATAR LA INFECCIÓN POR HEPATITIS B. | |
BR112019002117A2 (pt) | agente de rnai contra infecção do vírus da hepatite b | |
MX2021006635A (es) | Composiciones de acido ribonucleico de interferencia (arni) contra el virus de la hepatitis b (hbv) y metodos de uso de estas. | |
WO2017027350A3 (en) | Rnai therapy for hepatitis b virus infection | |
PH12020550436A1 (en) | NUCLEIC ACID MOLECULE FOR REDUCTION OF PAPD5 AND PAPD7 mRNA FOR TREATING HEPATITIS B INFECTION | |
PH12017500010A1 (en) | Methods for the treatment of hepatitis b and hepatitis d virus infections | |
MX2010009195A (es) | Rnas ultrapequeños como antagonistas del receptor tipo toll-3. | |
MX2021006745A (es) | Constructos de iarn modificados quimicamente y usos de estos. | |
CR20210015A (es) | Oligonucleótidos para modular la expresión de rtel 1 | |
BR112017018329A2 (pt) | composição para prevenir ou tratar calcificação de válvula, contendo inibidor de dpp-4 | |
JOP20210007A1 (ar) | تركيبات عامل dsRNA لفيروس التهاب الكبد الوبائي ب وطرق استخدامها | |
WO2009138146A3 (de) | Neue therapeutika für die hepatitis-therapie | |
CL2020001638A1 (es) | Molécula de ácidos nucleicos para la reducción del arnm de papd5 y papd7 en el tratamiento de la infección de la hepatitis b. (divisional solicitud 202000945) | |
WO2022038211A3 (en) | Use of a1cf inhibitors for treating hepatitis b virus infection | |
JP2018520150A5 (es) | ||
MX2022016280A (es) | Oligonucleotidos mejorados para modular la expresion de fubp1. | |
WO2021122921A8 (en) | Use of cops3 inhibitors for treating hepatitis b virus infection | |
PH12018502320A1 (en) | Reagents for treatment of hepatitis b virus (hbv) infection and use thereof | |
TW202424191A (zh) | 用於降低PAPD5及PAPD7 mRNA以治療B型肝炎感染之核酸分子 | |
EA202191771A1 (ru) | КОМПОЗИЦИИ НА ОСНОВЕ RNAi ПРОТИВ ВИРУСА ГЕПАТИТА В (HBV) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
JO3769B1 (ar) | علاج RNAi لعدوى فيروس التهاب الكبد B | |
BR112013027046A2 (pt) | "composto para modulação da expressão do vírus da hepatite b (hbv), composição farmacêutica e seus usos no tratamento de infecção pelo referido vírus ou para redução dos níveis de hbsag" | |
AR113771A1 (es) | Molécula de ácidos nucleicos para la reducción del arnm de papd5 y papd7 en el tratamiento de la infección de la hepatitis b | |
MA40218A (fr) | Procédés pour le traitement d'infections par le virus de l'hépatite b et le virus de l'hépatite d |